Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SSTR2-positive Tumors”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)Looking for participantsNCT07129252
What this trial is testing

Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Who this might be right for
SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc. 150
Testing effectiveness (Phase 2)Study completedNCT05410743
What this trial is testing

Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors

Who this might be right for
SSTR2-positive Tumors
The First Affiliated Hospital of Xiamen University 30
Very early researchLooking for participantsNCT06632860
What this trial is testing

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

Who this might be right for
Iodine-resistant Thyroid CancerMeningiomaNETs
Peking Union Medical College Hospital 40
Early research (Phase 1)Active Not RecruitingNCT05249114
What this trial is testing

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Providence Health & Services 6
Very early researchLooking for participantsNCT06632873
What this trial is testing

177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors

Who this might be right for
SSTR2 and Integrin αVβ3 Positive Tumors
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Looking for participantsNCT05636618
What this trial is testing

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+3 more
Perspective Therapeutics 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT03454763
What this trial is testing

Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors

Who this might be right for
Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 618
Testing effectiveness (Phase 2)Ended earlyNCT03697551
What this trial is testing

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
Ipsen 4